- Home
- GDTC vs TPST Comparison
GDTC vs TPST Comparison
Compare GDTC & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- TPST
- Stock Information
- Founded
- GDTC 2018
- TPST 2011
- Country
- GDTC Singapore
- TPST United States
- Employees
- GDTC N/A
- TPST N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- TPST Health Care
- Exchange
- GDTC Nasdaq
- TPST Nasdaq
- Market Cap
- GDTC 28.0M
- TPST 33.0M
- IPO Year
- GDTC 2023
- TPST N/A
- Fundamental
- Price
- GDTC $2.08
- TPST $7.13
- Analyst Decision
- GDTC Buy
- TPST Hold
- Analyst Count
- GDTC 1
- TPST 3
- Target Price
- GDTC $5.00
- TPST $30.00
- AVG Volume (30 Days)
- GDTC 5.7K
- TPST 251.1K
- Earning Date
- GDTC 01-01-0001
- TPST 08-07-2025
- Dividend Yield
- GDTC N/A
- TPST N/A
- EPS Growth
- GDTC N/A
- TPST N/A
- EPS
- GDTC N/A
- TPST N/A
- Revenue
- GDTC $368,838.00
- TPST N/A
- Revenue This Year
- GDTC $5.37
- TPST N/A
- Revenue Next Year
- GDTC N/A
- TPST N/A
- P/E Ratio
- GDTC N/A
- TPST N/A
- Revenue Growth
- GDTC N/A
- TPST N/A
- 52 Week Low
- GDTC $1.20
- TPST $5.35
- 52 Week High
- GDTC $4.05
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- GDTC 48.83
- TPST 51.19
- Support Level
- GDTC $2.07
- TPST $6.73
- Resistance Level
- GDTC $2.34
- TPST $7.18
- Average True Range (ATR)
- GDTC 0.09
- TPST 0.31
- MACD
- GDTC 0.00
- TPST -0.00
- Stochastic Oscillator
- GDTC 50.97
- TPST 84.48
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.